Loading
A phase 2 trial of Cretostimogene grenadenorepvec in bladder & urothelial cancer, run by Lepu Biopharma Co., Ltd., now recruiting.
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin is a phase 2 interventional study registered as NCT07283835 by Lepu Biopharma Co., Ltd., with 16 participants planned, started 2025-12-04 and due to reach its primary completion in 2027-12-31. Interventions recorded: Cretostimogene Grenadenorepvec.
Shares Cretostimogene grenadenorepvec, Non-muscle-invasive bladder cancer, Oncolytic viruses, Bladder & urothelial cancer and the tag pipeline.
Shares Cretostimogene grenadenorepvec, Non-muscle-invasive bladder cancer, Oncolytic viruses, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.